BRPI1015996A2 - composições farmacêuticas aquosas contendo complexos de borato-poliol - Google Patents

composições farmacêuticas aquosas contendo complexos de borato-poliol

Info

Publication number
BRPI1015996A2
BRPI1015996A2 BRPI1015996A BRPI1015996A BRPI1015996A2 BR PI1015996 A2 BRPI1015996 A2 BR PI1015996A2 BR PI1015996 A BRPI1015996 A BR PI1015996A BR PI1015996 A BRPI1015996 A BR PI1015996A BR PI1015996 A2 BRPI1015996 A2 BR PI1015996A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions containing
aqueous pharmaceutical
containing borate
polyol complexes
Prior art date
Application number
BRPI1015996A
Other languages
English (en)
Inventor
Bhagwati P Kabra
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42364357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015996(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI1015996A2 publication Critical patent/BRPI1015996A2/pt
Publication of BRPI1015996A8 publication Critical patent/BRPI1015996A8/pt
Publication of BRPI1015996B1 publication Critical patent/BRPI1015996B1/pt
Publication of BRPI1015996B8 publication Critical patent/BRPI1015996B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1015996A 2009-06-19 2010-06-17 composição oftálmica de múltiplas doses contendo complexos de borato-poliol. BRPI1015996B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21847209P 2009-06-19 2009-06-19
US61/218,472 2009-06-19
PCT/US2010/038979 WO2010148190A1 (en) 2009-06-19 2010-06-17 Aqueous pharmaceutical compositions containing borate-polyol complexes

Publications (4)

Publication Number Publication Date
BRPI1015996A2 true BRPI1015996A2 (pt) 2016-04-26
BRPI1015996A8 BRPI1015996A8 (pt) 2018-01-09
BRPI1015996B1 BRPI1015996B1 (pt) 2020-08-11
BRPI1015996B8 BRPI1015996B8 (pt) 2021-05-25

Family

ID=42364357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015996A BRPI1015996B8 (pt) 2009-06-19 2010-06-17 composição oftálmica de múltiplas doses contendo complexos de borato-poliol.

Country Status (27)

Country Link
US (3) US9044484B2 (pt)
EP (4) EP2442790B1 (pt)
JP (3) JP6017956B2 (pt)
KR (1) KR101738502B1 (pt)
CN (2) CN104707145A (pt)
AR (2) AR077126A1 (pt)
AU (1) AU2010262898B2 (pt)
BR (1) BRPI1015996B8 (pt)
CA (1) CA2763778C (pt)
CL (1) CL2010000634A1 (pt)
CY (2) CY1117835T1 (pt)
DK (3) DK2442790T3 (pt)
ES (3) ES2803648T3 (pt)
HK (2) HK1163521A1 (pt)
HR (2) HRP20160953T1 (pt)
HU (2) HUE030435T2 (pt)
LT (1) LT3045164T (pt)
MX (1) MX2011013107A (pt)
PL (3) PL2722035T3 (pt)
PT (3) PT2442790E (pt)
RU (1) RU2563125C2 (pt)
SI (3) SI2722035T1 (pt)
SM (1) SMT201600249B (pt)
TW (1) TWI489997B (pt)
UY (1) UY32709A (pt)
WO (1) WO2010148190A1 (pt)
ZA (1) ZA201108384B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232763A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
BR112013018025A2 (pt) 2011-01-18 2020-10-27 Senju Pharmaceutical Co., Ltd composição de bromfenac líquida aquosa método para reforçar a eficácia conservante de uma solução aquosa
JP2014512387A (ja) 2011-04-22 2014-05-22 アルコン リサーチ， リミテッド 二つの異なる粘性増強剤を有する粘性増強システムを備えた眼科用組成物
CA2833591A1 (en) 2011-04-22 2012-10-26 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
ES2835398T3 (es) 2013-02-01 2021-06-22 Ocuphire Pharma Inc Métodos y composiciones para la administración oftálmica diaria de fentolamina para mejorar el rendimiento visual
ES2762153T3 (es) 2013-02-01 2020-05-22 Ocuphire Pharma Inc Soluciones oftálmicas acuosas de fentolamina y usos médicos de las mismas
WO2015026548A1 (en) 2013-08-20 2015-02-26 3M Innovative Properties Company Boron-silane polyether complex
WO2017217450A1 (ja) * 2016-06-15 2017-12-21 千寿製薬株式会社 眼科用医薬製品
JP6247430B1 (ja) * 2016-06-15 2017-12-13 千寿製薬株式会社 眼科用医薬製品
CN106237337B (zh) * 2016-08-05 2019-11-08 河南中帅医药科技股份有限公司 一种液体药物制剂用防腐组合物
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
JP7413040B2 (ja) 2018-02-21 2024-01-15 三菱重工サーマルシステムズ株式会社 スクロール流体機械及びその設計方法
EP3870170A4 (en) 2018-10-26 2022-07-20 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
PT3769753T (pt) 2019-07-23 2022-02-15 Nicox Ophthalmics Inc Processo para a preparação de suspensões aquosas oftálmicas estéreis de nanocristais de forma a de propianato de fluticasona
US20230218611A1 (en) 2020-04-29 2023-07-13 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
US20220105101A1 (en) 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Efficient brinzolamide and brimonidine compositions
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) * 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
GB2084870B (en) * 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
JP3058656B2 (ja) 1990-06-18 2000-07-04 トーメー産業株式会社 コンタクトレンズ用液剤組成物及びそれを用いたコンタクトレンズの洗浄若しくは保存方法
CA2098299C (en) * 1990-12-27 1997-05-20 Mary Mowrey-Mckee Method and composition for disinfecting contact lenses
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
JP2873530B2 (ja) * 1991-12-13 1999-03-24 参天製薬株式会社 ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5300287A (en) * 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en) * 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
CA2088927A1 (en) 1993-02-11 1994-08-12 Donald Skeffington Preservative system for vitamin e aqueous solution
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (pt) 1993-11-12 1996-04-21 Ciba Geigy Ag
WO1996003158A1 (en) * 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6024954A (en) * 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP0817607A1 (en) * 1995-03-20 1998-01-14 Unilever Plc Liquid cleansing formulations
US5683993A (en) * 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) * 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
AU4428397A (en) * 1996-09-20 1998-04-14 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) * 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
JPH10130156A (ja) * 1996-10-30 1998-05-19 Teika Seiyaku Kk 点眼剤組成物
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
ES2262603T3 (es) * 1996-12-13 2006-12-01 Alcon Laboratories, Inc. Composiciones oftalmicas que comprenden aminoalcoholes.
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
ES2206965T3 (es) * 1997-07-29 2004-05-16 Alcon Laboratories, Inc. Composiciones oftalmicas que contienen polimeros de galactomanana y borato.
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6034043A (en) * 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
JP4322503B2 (ja) * 2000-11-29 2009-09-02 ノバルティス アクチエンゲゼルシャフト 水性消毒系
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4844706B2 (ja) * 2001-03-12 2011-12-28 ライオン株式会社 眼科用組成物
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
TWI322828B (en) * 2002-12-23 2010-04-01 Alcon Inc Use of multifunctional surface active agents to clean contact lenses
CN100341498C (zh) * 2003-01-21 2007-10-10 千寿制药株式会社 含有2－氨基－3－(4－溴苯甲酰基)苯乙酸的水成液制剂
DK1692092T3 (da) * 2003-12-09 2009-06-22 Alcon Inc Anvendelse af bis-aminer til forstærkning af den antimikrobielle aktivitet af vandige sammensætninger
CA2545962A1 (en) 2003-12-09 2005-07-07 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
EP1696878A1 (en) * 2003-12-11 2006-09-06 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) * 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
JP2008515982A (ja) * 2004-10-13 2008-05-15 メルク エンド カムパニー インコーポレーテッド 高眼圧症を治療するための眼科組成物
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US20070212420A1 (en) * 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) * 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
WO2008002118A1 (es) 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
ZA200901164B (en) * 2006-09-21 2010-06-30 Alcon Res Ltd Self preserved aqueous pharmaceutical compositions
EP2066300B2 (en) 2006-09-28 2019-01-23 Novartis Ag Self-preserved aqueous pharmaceutical compositions
US20080093247A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US20080095863A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
US7705112B2 (en) 2007-04-17 2010-04-27 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
US20090232763A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
US7999064B2 (en) 2009-04-23 2011-08-16 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods and associated formulations
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物

Also Published As

Publication number Publication date
ES2803648T3 (es) 2021-01-28
PT3045164T (pt) 2020-07-14
JP2016183198A (ja) 2016-10-20
CN102802604A (zh) 2012-11-28
CY1117835T1 (el) 2017-05-17
SI3045164T1 (sl) 2020-08-31
PT2442790E (pt) 2014-05-12
AR122017A2 (es) 2022-08-03
DK3045164T3 (da) 2020-07-13
TWI489997B (zh) 2015-07-01
HUE030435T2 (en) 2017-05-29
HK1194007A1 (zh) 2014-10-10
RU2012101782A (ru) 2013-07-27
KR101738502B1 (ko) 2017-05-22
RU2563125C2 (ru) 2015-09-20
HRP20160953T1 (hr) 2016-10-07
CA2763778C (en) 2016-02-02
JP2012530712A (ja) 2012-12-06
PL2442790T3 (pl) 2014-08-29
CY1123120T1 (el) 2021-10-29
BRPI1015996B1 (pt) 2020-08-11
ES2461617T3 (es) 2014-05-20
EP3045164A1 (en) 2016-07-20
EP2722035B1 (en) 2016-04-27
LT3045164T (lt) 2020-07-27
KR20120028390A (ko) 2012-03-22
CL2010000634A1 (es) 2011-03-11
HUE049477T2 (hu) 2020-09-28
ES2584858T3 (es) 2016-09-29
CN104707145A (zh) 2015-06-17
AU2010262898A1 (en) 2011-12-15
SI2722035T1 (sl) 2016-09-30
EP3045164B1 (en) 2020-04-15
HK1163521A1 (en) 2012-09-14
EP2442790B1 (en) 2014-03-26
US9421265B2 (en) 2016-08-23
UY32709A (es) 2010-12-31
HRP20200979T1 (hr) 2020-10-16
AU2010262898B2 (en) 2015-02-12
CA2763778A1 (en) 2010-12-23
ZA201108384B (en) 2013-01-30
WO2010148190A1 (en) 2010-12-23
BRPI1015996A8 (pt) 2018-01-09
US20160324967A1 (en) 2016-11-10
SI2442790T1 (sl) 2014-05-30
PT2722035T (pt) 2016-08-02
DK2722035T3 (en) 2016-08-01
PL2722035T3 (pl) 2016-11-30
JP6017956B2 (ja) 2016-11-02
JP2014198729A (ja) 2014-10-23
EP3437634A1 (en) 2019-02-06
AR077126A1 (es) 2011-08-03
TW201100103A (en) 2011-01-01
US20100324031A1 (en) 2010-12-23
SMT201600249B (it) 2016-08-31
EP2442790A1 (en) 2012-04-25
EP2722035A1 (en) 2014-04-23
US9044484B2 (en) 2015-06-02
DK2442790T3 (da) 2014-04-14
BRPI1015996B8 (pt) 2021-05-25
CN102802604B (zh) 2016-02-10
PL3045164T3 (pl) 2020-10-19
US20150224196A1 (en) 2015-08-13
MX2011013107A (es) 2012-01-20

Similar Documents

Publication Publication Date Title
BRPI1015996A2 (pt) composições farmacêuticas aquosas contendo complexos de borato-poliol
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI0909738A2 (pt) composições farmacêuticas aquosas contendo complexos de boratopoliol
DK3097925T3 (da) Farmaceutisk sammensætning
DK2395834T3 (da) Natriumnitrit-holdige farmaceutiske sammensætninger
BRPI1004940A2 (pt) composição farmacêutica
IT1394860B1 (it) Composti farmaceutici
SMT201400069B (it) Formulazione farmaceutica
BRPI1012539A2 (pt) composições farmacêuticas
BRPI1015939A2 (pt) composição farmacêutica
IT1394400B1 (it) Composizioni farmaceutiche
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BRPI0922653A2 (pt) preparação farmacêutica
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
IT1393930B1 (it) Composti farmaceutici
BR112012003149A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas
BRPI1006076A2 (pt) composicoes farmaceuticas
IT1395724B1 (it) Composti farmaceutici
BRPI1008983A2 (pt) formulação farmacêutica
ITMI20100232A1 (it) Composti farmaceutici
DOP2009000016A (es) Composicion farmaceutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/00 , A61K 31/335 , A61K 31/52 , A61K 31/542 , A61K 47/02 , A61K 47/10 , A61K 47/18 , A61K 47/32

Ipc: A61K 47/18 (2017.01), A61K 31/498 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF